Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 89
Filtrar
1.
Psychopharmacology (Berl) ; 229(4): 579-89, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23722830

RESUMO

RATIONALE: Hypersignaling of corticotropin releasing factor (CRF) has been implicated in stress disorders; however, many of its downstream mechanisms of action remain unclear. In vitro, CRF1 receptor activation initiates multiple cell signaling cascades, including protein kinase A (PKA), protein kinase C (PKC), and mitogen-activated protein kinase kinase MEK1/2 signaling. It is unclear, however, which of these signaling cascades mediate CRF-induced behaviors during stress. OBJECTIVES: We examined the role of PKA, PKC, and MEK1/2 signaling pathways in CRF-induced anxiety as measured by startle hyperreactivity. METHODS: Mice treated with intracerbroventricular (ICV) ovine CRF (oCRF) were pretreated with the PKA inhibitor Rp-cAMPS, PKC inhibitor bisindolylmaleimide (BIM), or MEK1/2 inhibitor PD98059 (ICV) and assessed for acoustic startle reactivity. RESULTS: The PKC inhibitor BIM significantly attenuated CRF-induced increases in startle. BIM was also able to block startle increases induced by oCRF when both compounds were infused directly into the bed nucleus of stria terminalis (BNST). PKA and MEK1/2 inhibition had no significant effects on CRF-induced changes in startle at the dose ranges tested. CRF-induced disruption of prepulse inhibition was not significantly reversed by any of the three pretreatments at the dose ranges tested. CONCLUSIONS: PKC signaling is required for CRF-induced increases in startle, and this effect is mediated at least in part at the BNST. These findings suggest that PKC signaling cascades (1) may be important for the acute effects of CRF to induce startle hyperreactivity and (2) support further research of the role of PKC signaling in startle abnormalities relevant to disorders such as posttraumatic stress disorder.


Assuntos
Hormônio Liberador da Corticotropina/metabolismo , Proteína Quinase C/metabolismo , Reflexo de Sobressalto/fisiologia , Estresse Psicológico/fisiopatologia , Animais , Ansiedade/fisiopatologia , Hormônio Liberador da Corticotropina/administração & dosagem , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , MAP Quinase Quinase 1/metabolismo , MAP Quinase Quinase 2/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Inibidores de Proteínas Quinases/farmacologia , Reflexo de Sobressalto/efeitos dos fármacos , Núcleos Septais/metabolismo , Ovinos , Transdução de Sinais , Transtornos de Estresse Pós-Traumáticos/fisiopatologia
2.
Genes Brain Behav ; 11(5): 539-44, 2012 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-22471516

RESUMO

Self-esteem and well-being are important for successful aging, and some evidence suggests that self-esteem and well-being are associated with hippocampal volume, cognition and stress responsivity. Whereas most of this evidence is based on studies on older adults, we investigated self-esteem, well-being and hippocampal volume in 474 male middle-aged twins. Self-esteem was significantly positively correlated with hippocampal volume (0.09, P = 0.03 for left hippocampus, 0.10, P = 0.04 for right). Correlations for well-being were not significant (Ps > 0.05). There were strong phenotypic correlations between self-esteem and well-being (0.72, P < 0.001) and between left and right hippocampal volume (0.72, P < 0.001). In multivariate genetic analyses, a two-factor additive genetic and unique environmental (AE) model with well-being and self-esteem on one factor and left and right hippocampal volumes on the other factor fits the data better than Cholesky, independent pathway or common pathway models. The correlation between the two genetic factors was 0.12 (P = 0.03); the correlation between the environmental factors was 0.09 (P > 0.05). Our results indicate that largely different genetic and environmental factors underlie self-esteem and well-being on one hand and hippocampal volume on the other.


Assuntos
Hipocampo/anatomia & histologia , Tamanho do Órgão/fisiologia , Satisfação Pessoal , Autoimagem , Envelhecimento/genética , Envelhecimento/psicologia , Humanos , Masculino , Pessoa de Meia-Idade , Modelos Psicológicos
3.
Chronobiol Int ; 22(4): 695-709, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16147900

RESUMO

There is evidence that aging may impair phase-shifting responses to light synchronizers, which could lead to disturbed or malsynchronized circadian rhythms. To explore this hypothesis, 62 elder participants (age, 58 to 84 years) and 25 young adults (age, 19 to 40 years) were studied, first with baseline 1-wk wrist actigraphy at home and then by 72 h in-laboratory study using an ultra-short sleep-wake cycle. Subjects were awake for 60 minutes in 50 lux followed by 30 minutes of darkness for sleep. Saliva samples were collected for melatonin, and urine samples were collected for aMT6s (a urinary metabolite of melatonin) and free cortisol every 90 minutes. Oral temperatures were also measured every 90 minutes. The timing of the circadian rhythms was not significantly more variable among the elders. The times of lights-out and wake-up at home and urinary free cortisol occurred earlier among elders, but the acrophases (cosinor analysis-derived peak time) of the circadian rhythm of salivary melatonin, urinary aMT6s, and oral temperature were not significantly phase-advanced among elders. The estimated duration of melatonin secretion was 9.9 h among elders and 8.4 h among young adults (p < 0.025), though the estimated half-life of blood melatonin was shorter among elders (p < 0.025), and young adults had higher saliva melatonin and urinary aMT6s levels. In summary, there was no evidence for circadian desynchronization associated with aging, but there was evidence of some rearrangement of the internal phase-angles among the studied circadian rhythms.


Assuntos
Envelhecimento/fisiologia , Ritmo Circadiano/fisiologia , Adulto , Idoso , Temperatura Corporal/fisiologia , Humanos , Hidrocortisona/urina , Melatonina/análogos & derivados , Melatonina/análise , Melatonina/metabolismo , Melatonina/urina , Pessoa de Meia-Idade , Saliva/química
4.
Psychoneuroendocrinology ; 28(6): 796-808, 2003 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-12812865

RESUMO

BACKGROUND: The experience of intimate partner violence (physical and sexual violence) has been linked to psychiatric disorders such as posttraumatic stress disorder, yet data on the neuroendocrine profile in this population is sparse. This study sought to examine baseline plasma cortisol and neuropeptide Y (NPY) levels in female victims of intimate partner violence (IPV). METHODS: Morning plasma samples were collected for cortisol and NPY determination in 22 women with histories of IPV (10 with current PTSD, 12 without current or lifetime PTSD) and 16 non-abused controls. RESULTS: Mean cortisol levels were significantly lower in IPV subjects compared with controls, but did not distinguish IPV subjects with and without PTSD. There were no significant differences in mean NPY levels between the groups. Neither cortisol nor NPY levels were significantly correlated with PTSD symptoms. CONCLUSIONS: These preliminary findings suggest that victims of IPV, like women traumatized by childhood abuse, may be characterized by alterations in hypothalamic-pituitary-adrenal axis functioning, however, further study is needed to identify specific stress system disturbances in this group.


Assuntos
Violência Doméstica , Hidrocortisona/sangue , Neuropeptídeo Y/sangue , Transtornos de Estresse Pós-Traumáticos/fisiopatologia , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Pessoa de Meia-Idade , Testes Neuropsicológicos
5.
Mol Psychiatry ; 8(5): 546-57, 2003 May.
Artigo em Inglês | MEDLINE | ID: mdl-12808434

RESUMO

In a genome-wide linkage survey, we have previously shown evidence suggesting that the chromosome 22q12 region contains a susceptibility locus for bipolar disorder (BPD). Two independent family sets yielded lod scores suggestive of linkage at markers in this region near the gene G protein receptor kinase 3 (GRK3). GRK3 is an excellent candidate risk gene for BPD since GRK3 is expressed widely in the brain, and since GRKs play key roles in the homologous desensitization of G protein-coupled receptor signaling. We have also previously shown GRK3 expression to be induced by amphetamine in an animal model of mania using microarray-based expression profiling. To identify possible functional mutations in GRK3, we sequenced the putative promoter region, all 21 exons, and intronic sequence flanking each exon, in 14-22 individuals with BPD. We found six sequence variants in the 5'-UTR/promoter region, but no coding or obvious splice variants. Transmission disequilibrium analyses of one set of 153 families indicated that two of the 5'-UTR/promoter variants are associated with BPD in families of northern European Caucasian ancestry. A supportive trend towards association to one of these two variants (P-5) was then subsequently obtained in an independent sample of 237 families. In the combined sample, the P-5 variant had an estimated allele frequency of 3% in bipolar subjects, and displayed a transmission to non-transmission ratio of 26 : 7.7 (chi(2)=9.6, one-sided P value=0.0019). Altogether, these data support the hypothesis that a dysregulation in GRK3 expression alters signaling desensitization, and thereby predisposes to the development of BPD.


Assuntos
Transtorno Bipolar/genética , Cromossomos Humanos Par 22 , Desequilíbrio de Ligação , Polimorfismo de Nucleotídeo Único , Proteínas Serina-Treonina Quinases/genética , Animais , Sequência de Bases , Quinase 3 de Receptor Acoplado a Proteína G , Genoma Humano , Humanos , Camundongos , Dados de Sequência Molecular , Fenótipo , Regiões Promotoras Genéticas/genética
6.
J Neuroendocrinol ; 14(2): 126-34, 2002 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-11849372

RESUMO

The Wistar-Kyoto (WKY) rat shows signs of persistent activation of the hypothalamic-pituitary-adrenal axis, but the cause and site of this activation is not yet known. Chronically activated corticotrophs generally show blunted adrenocorticotropic hormone (ACTH) response to corticotropin releasing factor (CRF); therefore, the anterior pituitary responsiveness to ACTH secretagogues, CRF and vasopressin, was compared in male WKY and Wistar rats. Anterior pituitary CRF binding and CRF receptor mRNA expression was significantly decreased in WKY rats. ACTH response to CRF or vasopressin was markedly impaired, and vasopressin failed to potentiate the CRF-stimulated ACTH release in cultured WKY anterior pituitary cells. In contrast, CRF and vasopressin alone and in combination stimulated large, concentration-dependent increases in ACTH release in Wistar anterior pituitary cells. By contrast to the decreased ACTH secretory responses, steady-state anterior pituitary pro-opiomelanocortin mRNA levels were approximately 12-fold greater in WKY rats compared to Wistar rats, and they further increased in response to CRF stimulation. These findings suggest that, although the WKY rat corticotroph is under a chronic state of activation or disinhibition, the in vitro secretory responses to classic ACTH secretagogues are impaired.


Assuntos
Hormônio Adrenocorticotrópico/metabolismo , Adeno-Hipófise/metabolismo , Receptores de Hormônio Liberador da Corticotropina/genética , Animais , Células Cultivadas , Hormônio Liberador da Corticotropina/farmacologia , Transtorno Depressivo Maior/fisiopatologia , Expressão Gênica/efeitos dos fármacos , Expressão Gênica/fisiologia , Masculino , Adeno-Hipófise/citologia , Pró-Opiomelanocortina/genética , RNA Mensageiro/análise , Ratos , Ratos Endogâmicos WKY , Ratos Wistar , Receptores de Hormônio Liberador da Corticotropina/metabolismo , Especificidade da Espécie , Vasoconstritores/farmacologia , Vasopressinas/farmacologia
7.
Peptides ; 22(5): 753-60, 2001 May.
Artigo em Inglês | MEDLINE | ID: mdl-11337088

RESUMO

Dysfunctioning of corticotropin-releasing hormone (CRH) and its receptors (CRH(1) and CRH(2)) has been linked to the development of stress-related disorders, such as mood and eating disorders. The molecular characterization of CRH(1) and CRH(2) receptors and their splice variants has generated detailed information on their pharmacology, tissue distribution and physiology. While mammalian CRH(1) receptors nonselectively bind CRH analogs, the ligand specificity of CRH(2) is narrower. CRH(1) receptors are predominantly expressed in the brain and pituitary, whereas CRH(2) receptor expression is limited to particular brain areas and to some peripheral organs. Molecular approaches to block CRH(1) receptor expression in the brain argue in favor of its involvement in the regulation of some aspects of the stress response. The CRH(2alpha) receptor may be more important for motivational types of behavior essential for survival, such as feeding and defense.(1)


Assuntos
Comportamento Animal/fisiologia , Hormônio Liberador da Corticotropina/metabolismo , Receptores de Hormônio Liberador da Corticotropina/metabolismo , Afeto/fisiologia , Processamento Alternativo , Animais , Sítios de Ligação , Encéfalo/metabolismo , Humanos , Ligantes , Camundongos , Camundongos Transgênicos , Hipófise/química , Estrutura Terciária de Proteína , Ratos , Receptores de Hormônio Liberador da Corticotropina/deficiência , Receptores de Hormônio Liberador da Corticotropina/genética
8.
Am J Physiol Regul Integr Comp Physiol ; 280(4): R935-46, 2001 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-11247813

RESUMO

Potential G protein-coupled receptor kinase (GRK) and protein kinase A (PKA) mediation of homologous desensitization of corticotropin-releasing factor type 1 (CRF1) receptors was investigated in human retinoblastoma Y-79 cells. Inhibition of PKA activity by PKI(5-22) or H-89 failed to attenuate homologous desensitization of CRF1 receptors, and direct activation of PKA by forskolin or dibutyryl cAMP failed to desensitize CRF-induced cAMP accumulation. However, treatment of permeabilized Y-79 cells with heparin, a nonselective GRK inhibitor, reduced homologous desensitization of CRF1 receptors by approximately 35%. Furthermore, Y-79 cell uptake of a GRK3 antisense oligonucleotide (ODN), but not of a random or mismatched ODN, reduced GRK3 mRNA expression by approximately 50% without altering GRK2 mRNA expression and inhibited homologous desensitization of CRF1 receptors by approximately 55%. Finally, Y-79 cells transfected with a GRK3 antisense cDNA construct exhibited an approximately 50% reduction in GRK3 protein expression and an ~65% reduction in homologous desensitization of CRF1 receptors. We conclude that GRK3 contributes importantly to the homologous desensitization of CRF1 receptors in Y-79 cells, a brain-derived cell line.


Assuntos
Proteínas Serina-Treonina Quinases/metabolismo , Receptores de Hormônio Liberador da Corticotropina/fisiologia , Sulfonamidas , Colforsina/farmacologia , Proteínas Quinases Dependentes de AMP Cíclico/antagonistas & inibidores , Proteínas Quinases Dependentes de AMP Cíclico/genética , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , DNA Antissenso , Inibidores Enzimáticos/farmacologia , Neoplasias Oculares , Quinase 3 de Receptor Acoplado a Proteína G , Regulação Enzimológica da Expressão Gênica/efeitos dos fármacos , Regulação Enzimológica da Expressão Gênica/fisiologia , Humanos , Isoquinolinas/farmacologia , Oligodesoxirribonucleotídeos Antissenso/farmacologia , Fragmentos de Peptídeos/farmacologia , Proteínas Serina-Treonina Quinases/genética , RNA Mensageiro/genética , Receptores de Hormônio Liberador da Corticotropina/efeitos dos fármacos , Receptores de Hormônio Liberador da Corticotropina/genética , Proteínas Recombinantes/metabolismo , Retinoblastoma , Transcrição Gênica/efeitos dos fármacos , Transfecção , Células Tumorais Cultivadas , Quinases de Receptores Adrenérgicos beta
9.
Neuropharmacology ; 40(3): 394-407, 2001 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-11166332

RESUMO

Pituitary adenylyl cyclase-activating polypeptide (PACAP) receptor type 1 (PAC(1)) signaling and desensitization were investigated in human retinoblastoma Y-79 cells. Concentration-dependent stimulation of cAMP accumulation was observed in Y-79 cells incubated for 30 min with PACAP38, PACAP27, or VIP (10(-12) to 10(-6) M). The following EC(50) values were calculated: PACAP38, 24+/-3 pM; PACAP27, 99+/-8 pM; and VIP, 29+/-3 nM. Homologous desensitization of PAC(1) receptors in Y-79 cells pretreated with 10 nM PACAP38 or PACAP27 for 60 min was characterized by a 30-50% reduction in PACAP-stimulated cAMP accumulation (p<0.0001) and a two- to fivefold rightward shift in EC(50) values (p<0.0001). PAC(1) receptor desensitization was not accompanied by a reduction in PAC(1) mRNA expression. We concluded that the desensitizing effect of PACAP38 was homologous because neither corticotropin-releasing factor- nor (-)-isoproterenol-stimulated cAMP accumulation was altered by PACAP38 preincubation. Pretreating Y-79 cells with the protein kinase A (PKA) inhibitor H89 failed to inhibit homologous PAC(1) receptor desensitization. Similarly, pretreating Y-79 cells with the protein kinase C (PKC) inhibitors staurosporine or bisindolylmaleimide failed to alter homologous PAC(1) receptor desensitization. Although activation of PKA by dibutyryl cAMP or forskolin did not desensitize PAC(1) receptors, direct activation of PKC by PMA heterologously desensitized PAC(1) receptors, reducing cAMP accumulation 34.2+/-2.2% (p<0.001). Using RT-PCR, mRNA levels for G-protein-coupled receptor kinase 3 (GRK3), but not GRK2, were found to increase 2.2- to 4.8-fold in Y-79 cells exposed to PACAP38 for 10 min to 24 h (p<0.001). PAC(1) receptor desensitization decreased 72.5+/-4.3% (p<0.001) in Y-79 cells transfected with a GRK3 antisense cDNA construct that also reduced GRK3 protein expression 48.5+/-7.9% (p<0.0005). These experiments demonstrate that GRK3 plays an important role in the homologous desensitization of retinoblastoma PAC(1) receptors, whereas PKC, but not PKA, contributes to the heterologous desensitization of retinoblastoma PAC(1) receptors.


Assuntos
Proteína Quinase C/metabolismo , Proteínas Serina-Treonina Quinases/metabolismo , Receptores do Hormônio Hipofisário/metabolismo , Retinoblastoma/metabolismo , Transdução de Sinais/fisiologia , Agonistas Adrenérgicos beta/farmacologia , Processamento Alternativo , Hormônio Liberador da Corticotropina/farmacologia , AMP Cíclico/metabolismo , Proteínas Quinases Dependentes de AMP Cíclico/antagonistas & inibidores , Proteínas Quinases Dependentes de AMP Cíclico/metabolismo , DNA Antissenso/farmacologia , Inibidores Enzimáticos/farmacologia , Quinase 3 de Receptor Acoplado a Proteína G , Humanos , Líquido Intracelular/metabolismo , Neuropeptídeos/farmacologia , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Proteína Quinase C/antagonistas & inibidores , Proteínas Serina-Treonina Quinases/antagonistas & inibidores , Proteínas Serina-Treonina Quinases/genética , RNA Mensageiro/metabolismo , Receptores Adrenérgicos beta/metabolismo , Receptores de Hormônio Liberador da Corticotropina/metabolismo , Receptores de Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Receptores de Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Receptores do Hormônio Hipofisário/genética , Transdução de Sinais/efeitos dos fármacos , Células Tumorais Cultivadas , Peptídeo Intestinal Vasoativo/farmacologia
10.
Peptides ; 22(12): 2083-9, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11786194

RESUMO

Corticotropin-releasing factor (CRF) is a 41 amino acid neuropeptide which is involved in the stress response. CRF and neuropeptide Y (NPY) produce reciprocal effects on anxiety in the central nucleus of the amygdala. The molecular mechanisms of possible CRF-NPY interactions in regulating anxiety behavior is not known. In the central nervous system, the action of NPY leads to inhibition of cAMP production while CRF is known to stimulate levels of cAMP in the brain. Consequently, we hypothesized that NPY may antagonize anxiety-like behavior by counter-regulating CRF-stimulated cAMP accumulation and activation of the protein kinase A pathway. We have engineered an immortalized amygdalar cell line (AR-5 cells) which express via RT-PCR, the CRF(2alpha), Y(1) and Y(5) NPY receptor. In addition, in these cells CRF treatment results in significant concentration-dependent increases in cAMP production. Furthermore, incubation of 3 microM CRF with increasing concentrations of NPY was able to significantly inhibit the increases in cAMP compared to that observed with 3 microM CRF treatment alone. These findings suggest that CRF and NPY may counter-regulate each other in amygdalar neurons via reciprocal effects on the protein kinase A pathway.


Assuntos
Tonsila do Cerebelo/metabolismo , Hormônio Liberador da Corticotropina/metabolismo , Neuropeptídeo Y/metabolismo , Transdução de Sinais , Tonsila do Cerebelo/citologia , Animais , Sequência de Bases , Linhagem Celular Transformada , AMP Cíclico/metabolismo , Primers do DNA , Ligação Proteica , Receptores de Neuropeptídeo Y
11.
Physiol Genomics ; 4(1): 83-91, 2000 Nov 09.
Artigo em Inglês | MEDLINE | ID: mdl-11074017

RESUMO

We have used methamphetamine treatment of rats as an animal model for psychotic mania. Specific brain regions were analyzed comprehensively for changes in gene expression using oligonucleotide GeneChip microarrays. The data was cross-matched against human genomic loci associated with either bipolar disorder or schizophrenia. Using this convergent approach, we have identified several novel candidate genes (e.g., signal transduction molecules, transcription factors, metabolic enzymes) that may be involved in the pathogenesis of mood disorders and psychosis. Furthermore, for one of these genes, G protein-coupled receptor kinase 3 (GRK3), we found by Western blot analysis evidence for decreased protein levels in a subset of patient lymphoblastoid cell lines that correlated with disease severity. Finally, the classification of these candidate genes into two prototypical categories, psychogenes and psychosis-suppressor genes, is described.


Assuntos
Arilsulfotransferase , Transtorno Bipolar/genética , Proteínas de Caenorhabditis elegans , Genômica/métodos , Transtornos Psicóticos/genética , Proteínas Adaptadoras de Transdução de Sinal , Animais , Transtorno Bipolar/enzimologia , Transtorno Bipolar/metabolismo , Farnesil-Difosfato Farnesiltransferase/genética , Quinase 3 de Receptor Acoplado a Proteína G , Proteínas de Helminto/genética , Humanos , Fator de Crescimento Insulin-Like I/genética , Proteínas de Membrana/genética , Proteínas do Tecido Nervoso/genética , Oxirredutases/genética , Proteínas Serina-Treonina Quinases/genética , Transtornos Psicóticos/enzimologia , Transtornos Psicóticos/metabolismo , Ratos , Ratos Sprague-Dawley , Esquizofrenia/enzimologia , Esquizofrenia/genética , Esquizofrenia/metabolismo , Homologia de Sequência de Aminoácidos , Transdução de Sinais/genética , Sulfotransferases/genética , Proteínas de Transporte Vesicular
12.
J Clin Endocrinol Metab ; 85(10): 3597-603, 2000 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-11061508

RESUMO

The objective of this study was to evaluate the effects of nocturnal sleep, partial night sleep deprivation, and sleep stages on circulating concentrations of interleukin-6 (IL-6) in relation to the secretory profiles of GH, cortisol, and melatonin. In 31 healthy male volunteers, blood samples were obtained every 30 min during 2 nights: uninterrupted, baseline sleep and partial sleep deprivation-early night (awake until 0300 h). Sleep was measured by electroencephalogram polysomnography. Sleep onset was associated with an increase in serum levels of IL-6 (P < 0.05) during baseline sleep. During PSD-E, the nocturnal increase in IL-6 was delayed until sleep at 0300 h. Sleep stage analyses indicated that the nocturnal increase in IL-6 occurred in association with stage 1-2 sleep and rapid eye movement sleep, but levels during slow wave sleep were not different from those while awake. The profile of GH across the 2 nights was similar to that of IL-6, whereas the circadian-driven hormones cortisol and melatonin showed no concordance with sleep. Loss of sleep may serve to decrease nocturnal IL-6 levels, with effects on the integrity of immune system functioning. Alternatively, given the association between sleep stages and IL-6 levels, depressed or aged populations who show increased amounts of REM sleep and a relative loss of slow wave sleep may have elevated nocturnal concentrations of IL-6 with implications for inflammatory disease risk.


Assuntos
Hormônio do Crescimento Humano/sangue , Hidrocortisona/sangue , Interleucina-6/sangue , Melatonina/sangue , Privação do Sono , Sono/fisiologia , Adulto , Idoso , Eletroencefalografia/efeitos dos fármacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Fases do Sono/fisiologia
13.
Biol Psychiatry ; 47(10): 902-9, 2000 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-10807963

RESUMO

BACKGROUND: Neuropeptide-Y (NPY) is present in extensive neuronal systems of the brain and is present in high concentrations in cell bodies and terminals in the amygdala. Preclinical studies have shown that injections of NPY into the central nucleus of the amygdala function as a central anxiolytic and buffer against the effects of stress. The objective of this study was to assess plasma NPY immunoreactivity in healthy soldiers participating in high intensity military training at the U.S. Army survival school. The Army survival school provides a means of observing individuals under high levels of physical, environmental, and psychological stress, and consequently is considered a reasonable analogue to stress incurred as a result of war or other catastrophic experiences. METHODS: Plasma levels of NPY were assessed at baseline (prior to initiation of training), and 24 hours after the conclusion of survival training in 49 subjects, and at baseline and during the Prisoner of War (P.O.W.) experience (immediately after exposure to a military interrogation) in 21 additional subjects. RESULTS: Plasma NPY levels were significantly increased compared to baseline following interrogations and were significantly higher in Special Forces soldiers, compared to non-Special Forces soldiers. NPY elicited by interrogation stress was significantly correlated to the subjects' behavior during interrogations and tended to be negatively correlated to symptoms of reported dissociation. Twenty-four hours after the conclusion of survival training, NPY had returned to baseline in Special Forces soldiers, but remained significantly lower than baseline values in non-Special Forces soldiers. NPY was positively correlated with both cortisol and behavioral performance under stress. NPY was negatively related to psychological symptoms of dissociation. CONCLUSIONS: These results provide evidence that uncontrollable stress significantly increases plasma NPY in humans, and when extended, produces a significant depletion of plasma NPY. Stress-induced alterations of plasma NPY were significantly different in Special Forces soldiers compared to non-Special Forces soldiers. These data support the idea that NPY may be involved in the enhanced stress resilience seen in humans.


Assuntos
Militares/psicologia , Neuropeptídeo Y/sangue , Sobrevida/psicologia , Adulto , Encéfalo/metabolismo , Humanos , Hidrocortisona/sangue , Masculino , Transtornos de Estresse Pós-Traumáticos/psicologia , Estresse Fisiológico/psicologia
14.
Biol Psychiatry ; 47(6): 526-39, 2000 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-10715359

RESUMO

BACKGROUND: Consistent with many studies demonstrating enhanced reactivity of the sympathetic nervous system in posttraumatic stress disorder (PTSD), the administration of yohimbine, a noradrenergic alpha(2)-antagonist, has been shown to increase core symptoms of PTSD and to induce greater increases in plasma 3-methyl-4-hydroxy-phenyl-glycol (MHPG) in subjects with PTSD compared with healthy control subjects. In turn, neuropeptide Y (NPY) has been shown to inhibit the release of norepinephrine from sympathetic noradrenergic neurons. METHODS: In the following study, plasma NPY responses to yohimbine and placebo were measured in a subgroup of 18 subjects with PTSD and 8 healthy control subjects who participated in the previous study of the effect of yohimbine on plasma MHPG. RESULTS: The PTSD subjects had lower baseline plasma NPY and blunted yohimbine-stimulated increases in plasma NPY compared with the healthy control subjects. Within the PTSD group, baseline plasma NPY levels correlated negatively with combat exposure scale scores, baseline PTSD and panic symptoms, and yohimbine-stimulated increases in MHPG and systolic blood pressure. CONCLUSIONS: This study suggests that combat stress-induced decreases in plasma NPY may mediate, in part, the noradrenergic system hyperreactivity observed in combat-related PTSD. The persistence of this decrease in plasma NPY may contribute to symptoms of hyperarousal and the expression of exaggerated alarm reactions, anxiety reactions, or both in combat veterans with PTSD long after war.


Assuntos
Antagonistas Adrenérgicos alfa/sangue , Antagonistas Adrenérgicos alfa/farmacologia , Neuropeptídeo Y/metabolismo , Transtornos de Estresse Pós-Traumáticos/sangue , Ioimbina/sangue , Ioimbina/farmacologia , Adulto , Pressão Sanguínea/efeitos dos fármacos , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Metoxi-Hidroxifenilglicol/metabolismo , Transtorno de Pânico/sangue , Escalas de Graduação Psiquiátrica , Índice de Gravidade de Doença , Transtornos de Estresse Pós-Traumáticos/diagnóstico , Guerra
15.
Am J Physiol Regul Integr Comp Physiol ; 278(3): R684-91, 2000 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-10712289

RESUMO

Virgin, ovariectomized rats exposed to 2 wk of sequential estradiol (E(2)) and progesterone (P) followed by P withdrawal have increased hypothalamic oxytocin (OT) mRNA and peptide levels relative to sham-treated animals. This increase is prevented if P is sustained. In the central nervous system, P is metabolized to the neurosteroid allopregnanolone (3alpha-hydroxy-5alpha-pregnan-20-one), which exerts effects by acting as a positive allosteric modulator of GABA(A) receptor/Cl(-)-channel complexes. In the present study, ovariectomized rats that received sequential E(2) and P for 2 wk followed by P withdrawal were administered allopregnanolone at the time of P withdrawal. Hypothalamic and plasma allopregnanolone concentrations, serum E(2) and P concentrations, and hypothalamic OT mRNA levels were measured at death. Steroid-induced increases in OT mRNA were attenuated in animals treated with allopregnanolone at the time of P withdrawal. The results suggest that allopregnanolone plays an important modulatory role in steroid-mediated increases in hypothalamic OT.


Assuntos
Hipotálamo/metabolismo , Ocitocina/biossíntese , Pregnanolona/metabolismo , Progesterona/metabolismo , Animais , Estradiol/metabolismo , Estradiol/farmacologia , Feminino , Ovariectomia , Progesterona/farmacologia , Ratos
16.
Biochem Biophys Res Commun ; 268(2): 572-6, 2000 Feb 16.
Artigo em Inglês | MEDLINE | ID: mdl-10679245

RESUMO

Agonist-induced phosphorylation of the human corticotropin-releasing factor type 1 receptor (hCRF(1)-R) was investigated using an influenza hemagglutinin (HA) epitope-tagged receptor transiently expressed in COS-7 cells. The HA-hCRF(1)-R migrated as a broad band (M(r) 60,000-70,000) in SDS-PAGE and showed increased mobility (M(r) approximately 48,000) after enzymatic deglycosylation with peptide-N-glycosidase F, consistent with the predicted size (47 kDa) of the nonglycosylated HA-hCRF(1)-R protein. A marked increase in HA-hCRF(1)-R phosphorylation was observed in HA-hCRF(1)-R-expressing COS-7 cells exposed to 1 microM ovine CRF for 5 min, whereas activation of protein kinase A (PKA) by 50 microM forskolin, or of Ca(2+)/calmodulin (CaM)-dependent kinases by 10 microM ionomycin, had little effect. These findings are consistent with preliminary data suggesting that CRF(1)-R phosphorylation mediated by G protein receptor kinase 3 (GRK3), but not by PKA or CaM-dependent kinases, has an important role in the homologous desensitization of brain CRF(1)-Rs.


Assuntos
Receptores de Hormônio Liberador da Corticotropina/metabolismo , Animais , Células COS , Hormônio Liberador da Corticotropina/metabolismo , Humanos , Fosforilação , Receptores de Hormônio Liberador da Corticotropina/agonistas
17.
J Neuroendocrinol ; 11(12): 941-9, 1999 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-10583729

RESUMO

Three full-length cDNAs encoding functional splice variants of the pituitary adenylate cyclase-activating polypeptide (PACAP) type 1 receptor (PAC1) were isolated from Y-79 retinoblastoma cells and human cerebellum. Although the third intracellular loops of the three splice variants were identical, their N-terminal extracellular domains differed. The first full-length PAC1 variant, PAC1normal (PAC1n), encoded the entire N-terminus, whereas the second variant named PAC1short (PAC1s) was deleted by 21 amino acids (residues 89-109). Finally, the third variant, named PAC1very short (PAC1vs), was deleted by 57 amino acids (residues 53-109). Using semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) analysis, it was established that all three variants were expressed in neuronal tissues. Binding- and cAMP studies using human embryonic kidney 293 (HEK293) cells stably transfected with PAC1n, PAC1s and PAC1vs showed significant differences in the affinities and selectivities towards PACAP38, PACAP27 and VIP. PAC1n bound PACAP38 and PACAP27 with affinities in the low nanomolar range whereas VIP was bound with up to 400-fold lower affinity. PAC1vs preferentially bound PACAP38 (Ki=121 nM) and PACAP27 (Ki=129 nM) over VIP (Ki>1000 nM) but with 100-fold lower affinity than PAC1n. Surprisingly, PAC1s unselectively bound all three ligands with high affinity. These data indicate that residues 53-88 within the N-terminal domain of the PAC1 are important for high affinity ligand binding, whereas residues 89-109 determine the receptor's ligand selectivity.


Assuntos
Splicing de RNA/fisiologia , Receptores do Hormônio Hipofisário/genética , Receptores do Hormônio Hipofisário/metabolismo , Sítios de Ligação/genética , Ligação Competitiva/efeitos dos fármacos , Ligação Competitiva/fisiologia , Córtex Cerebral/citologia , Clonagem Molecular , AMP Cíclico/metabolismo , Humanos , Rim/citologia , Ligantes , Dados de Sequência Molecular , Neurônios/química , Neurônios/citologia , Neuropeptídeos/metabolismo , Neuropeptídeos/farmacologia , Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Estrutura Terciária de Proteína , Receptores de Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Receptores de Polipeptídeo Hipofisário Ativador de Adenilato Ciclase , Receptores do Hormônio Hipofisário/química , Retinoblastoma , Homologia de Sequência de Aminoácidos , Transfecção , Células Tumorais Cultivadas , Peptídeo Intestinal Vasoativo/farmacologia
18.
Behav Neurosci ; 113(3): 420-30, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10443770

RESUMO

The effects of various doses (40 microg/kg/hr, 300 microg/kg/hr, 600 microg/kg/hr or placebo) of hydrocortisone on tasks assessing working and declarative memory function were measured in 4 groups of 10 young men. During the infusion, participants were given an item-recognition working memory task, a paired-associate declarative memory task, and a continuous performance task used to control possible concomitant effects of corticosteroids on vigilance. The results revealed significant acute effects of the highest dose of hydrocortisone on working memory function, without any significant effect on declarative memory function or arousal-vigilance performance. These results suggest that working memory is more sensitive than declarative memory to the acute elevations of corticosteroids, which could explain the detrimental effects of corticosteroids on acquisition and consolidation of information, as reported in the literature.


Assuntos
Anti-Inflamatórios/efeitos adversos , Nível de Alerta/efeitos dos fármacos , Hidrocortisona/efeitos adversos , Memória/efeitos dos fármacos , Desempenho Psicomotor/efeitos dos fármacos , Hormônio Adrenocorticotrópico/sangue , Adulto , Análise de Variância , Glicemia/metabolismo , Relação Dose-Resposta a Droga , Humanos , Hidrocortisona/sangue , Masculino , Memória de Curto Prazo/efeitos dos fármacos , Rememoração Mental/efeitos dos fármacos , Testes Neuropsicológicos , Testes de Associação de Palavras
19.
J Neurochem ; 73(2): 821-9, 1999 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-10428081

RESUMO

The nonselective human corticotropin-releasing factor (hCRF) receptor 1 (hCRFR1) and the ligand-selective Xenopus CRFR1 (xCRFR1), xCRFR2, and hCRFR2alpha were compared. To understand the interactions of hCRF, ovine CRF (oCRF), rat urocortin (rUcn), and sauvagine, ligands with different affinities for type 1 and type 2 CRFRs, chimeric and mutant receptors of hCRFR1, xCRFR1, hCRFR2alpha, and xCRFR2 were constructed. In cyclic AMP stimulation and CRF-binding assays, it was established that different extracellular regions of CRFR1 and CRFR2 conferred their ligand selectivities. The ligand selectivity of xCRFR1 resided in five N-terminal amino acids, whereas the N-terminus of both CRFR2 proteins did not contribute to their ligand selectivities. Chimeric receptors in which the first extracellular domain of hCRFR1 replaced that of hCRFR2alpha or xCRFR2 showed a similar pharmacological profile to the two parental CRFR2 molecules. Chimeric receptors carrying the N-terminal domain of xCRFR1 linked to hCRFR2alpha or xCRFR2 displayed a novel pharmacological profile. hCRF, rUcn, and sauvagine were bound with high affinity, whereas oCRF was bound with low affinity. Furthermore, when three or five residues of xCRFR1 (Gln76, Gly81, Val83, His88, Leu89; or Gln76, Gly81, Val83) were introduced into receptor chimeras carrying the N-terminus of hCRFR1 linked to xCRFR2, the same novel pharmacology was observed. These data indicate a compensation mechanism of two differentially selecting regions located in different domains of both xCRFR1 and CRFR2.


Assuntos
Receptores de Hormônio Liberador da Corticotropina/química , Receptores de Hormônio Liberador da Corticotropina/genética , Proteínas de Anfíbios , Animais , Ligação Competitiva/fisiologia , Células Cultivadas , Hormônio Liberador da Corticotropina/metabolismo , Hormônio Liberador da Corticotropina/farmacologia , AMP Cíclico/metabolismo , Espaço Extracelular/química , Humanos , Radioisótopos do Iodo , Rim/citologia , Ligantes , Dados de Sequência Molecular , Mutagênese , Hormônios Peptídicos , Peptídeos/metabolismo , Peptídeos/farmacologia , Estrutura Terciária de Proteína , Ensaio Radioligante , Receptores de Hormônio Liberador da Corticotropina/metabolismo , Proteínas Recombinantes de Fusão/química , Proteínas Recombinantes de Fusão/genética , Proteínas Recombinantes de Fusão/metabolismo , Homologia de Sequência de Aminoácidos , Transfecção , Urocortinas , Vasodilatadores/metabolismo , Vasodilatadores/farmacologia , Xenopus
20.
J Neuroendocrinol ; 11(6): 419-28, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10336722

RESUMO

From brain, heart and muscle tissue of the tree shrew (Tupaia belangeri), a higher order mammal, cDNA clones were isolated that encoded two functional splice variants of the corticotropin-releasing factor (CRF) type 2 receptor (CRF-R2). The first, full-length splice variant, amplified from brain and heart tissue, encoded a CRF receptor protein that is 410 amino acids in length and approximately 96% homologous to human CRF-R2alpha. The second, full-length splice variant, derived from skeletal muscle tissue, encoded a 437-amino acid CRF receptor protein that is approximately 92% homologous to human CRF-R2beta. Semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR) amplifications and RNase protection analyses, showed that tree shrew CRF-R2alpha (tCRF-R2alpha) and tree shrew CRF-R2beta (tCRF-R2beta) were coexpressed in brain tissue but not in heart and skeletal muscle tissue. Finally, human embryonic kidney 293 (HEK293) cells stably transfected with tCRF-R2alpha and tCRF-R2beta were used to demonstrate that the CRF analogs urocortin and sauvagine bind with significantly greater affinity (21- to 140-fold) to these two CRF-R2 splice variants than do human/rat and ovine CRF analogs. In keeping with these results of our CRF binding studies, EC50 values were substantially lower for urocortin-and sauvagine-stimulated than for h/rCRF-and oCRF-stimulated cyclic AMP accumulation in HEK293 cells stably transfected with tCRF-R2alpha or tCRF-R2beta cDNAs. The tree shrew therefore constitutes an important animal model in which to investigate the role of CRF receptor subtypes in the stress response.


Assuntos
Receptores de Hormônio Liberador da Corticotropina/genética , Tupaia/metabolismo , Sequência de Aminoácidos , Animais , Linhagem Celular , Clonagem Molecular , AMP Cíclico/metabolismo , DNA Complementar/metabolismo , Humanos , Indicadores e Reagentes , Rim/citologia , Rim/metabolismo , Dados de Sequência Molecular , Músculo Esquelético/metabolismo , Miocárdio/metabolismo , Ensaio Radioligante , Receptores de Hormônio Liberador da Corticotropina/efeitos dos fármacos , Receptores de Hormônio Liberador da Corticotropina/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Ribonucleases/metabolismo , Distribuição Tecidual , Transfecção
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...